Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.
Missouri already spends $1.2 billion on Medicaid managed care in less than half its counties. The new plan would extend managed care to all Medicaid clients except the blind, disabled, and elderly. Meanwhile, in North Carolina, the CEO of the Medical Society argued against moving Medicaid to managed care, citing problems in other states.
Studies have shown that income is tied to most matters of health, including life expectancy, prevalence of diseases, and health behaviors. The Urban Institute and the Center on Society and Health have analyzed emerging evidence and prospects of income-related policies that work to improve population health.
Recent emphasis of identifying those with prediabetes and intervening to halt its progression is aimed at reducing the financial impact of diabetes in the United States, which was estimated in 2012 at $245 billion.